Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
Martin J. van den Bent(Erasmus MC Cancer Institute), Vassilis Golfinopoulos(Champalimaud Foundation), Michael Weller(University Hospital of Zurich), Joana Brilhante(Advantest (Singapore)), Pim J. French(Erasmus MC Cancer Institute), Iris de Heer(Erasmus MC Cancer Institute), Jim Looman(AbbVie (United States)), Sarah Nuyens(European Organisation for Research and Treatment of Cancer), Peter Ansell(AbbVie (United States)), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Jyotirmoy Dey(AbbVie (United States)), Scott Krause, Anna Maria Elisabeth Walenkamp(University Medical Center Groningen), Paul M. Clément(Universitair Ziekenhuis Leuven), Maarten Spruyt(European Organisation for Research and Treatment of Cancer), Hao Xiong(Shanghai Jiao Tong University)
Cited by 14
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k